Closed
Award Notice
Advance the development of SCY-247, a novel antifungal currently in Phase 1 clinical trials, for the treatment of invasive candidiasis and prophylaxis of invasive fungal disease as oral and IC formula
- Solicitation number
- BAA-23-100-SOL-00004
- Place of performance
- Jersey City, NJ
- Estimated value
- Up to $213.9M
- Closed
- Oct 2, 2026
- Posted
- Sep 25, 2026
Track this market for the recompete
This opportunity has closed. Follow NAICS and we'll alert you when the follow-on contract posts.